Chagas disease is a neglected tropical disease caused by the protozoan parasite Trypanosoma cruzi (T. cruzi) that affects an estimated 288,000 individuals living in the United States. Management of Chagas disease in immunosuppressed patients can be challenging. This is partly because T. cruzi reactivation is a known complication in transplant recipients, individuals with HIV, and those receiving immunosuppressive therapies. Clinical approaches to prevent and manage T. cruzi reactivation vary depending on the type of immunocompromise. Join Dr. Eva Clark, as part of our Summer Chagas Disease Webinar Series, for an exploration of the clinical management of Chagas disease in the immunosuppressed host. You will not want to miss it!

Learning Objectives:

1. Differentiate the clinical presentations of T. cruzi reactivation across immunocompromised populations, including people with HIV and solid organ transplant recipients.
2. Formulate an evidence-based management plan for T. cruzi reactivation disease, including selection of antitrypanosomal therapy, monitoring strategies, and secondary prophylaxis, tailored to the type of immunosuppression.
3. Identify patients at risk for Chagas disease who require serologic screening prior to initiation of immunosuppressive therapy or transplantation and apply current guideline-based screening recommendations to clinical practice.

Eva Clark, MD, PhD, CTropMed
Assistant Professor, Department of Medicine (Infectious Diseases) and Pediatrics (Tropical Medicine), Baylor College of Medicine

1.0 AMA PRA Category 1 Credits